1. A 26-year-old woman at 14 weeks gestation presents with tinea capitis confirmed by scalp culture as Trichophyton tonsurans. She asks whether any of the systemic antifungals covered in her reading — terbinafine, griseofulvin, or flucytosine — can be used safely during her pregnancy. Which statement most accurately describes the pregnancy safety profile of all three agents and identifies the most appropriate management approach?
A) Terbinafine is the preferred agent in pregnancy because it is the only systemic antifungal with an established favorable human safety record in the first and second trimesters; griseofulvin and flucytosine are contraindicated but terbinafine can be used at full dose without dose modification
B) All three agents are acceptable in the second trimester once organogenesis is complete; the teratogenic risk of griseofulvin and flucytosine applies only to the first trimester, and treatment can proceed at 14 weeks without restriction
C) All three agents should be avoided in pregnancy: griseofulvin is formally contraindicated due to teratogenicity in animal studies, flucytosine is teratogenic in animal models and is not recommended in human pregnancy, and terbinafine is not established as safe in pregnancy and is not recommended in the first trimester; treatment should be deferred if possible, and if systemic therapy is urgently required specialist input should guide selection of an alternative agent such as an oral azole
D) Griseofulvin is the preferred agent in pregnancy because it is a natural product derived from Penicillium griseofulvum and has been used for decades; natural product origin confers an inherently favorable teratogenic profile not shared by synthetic agents such as terbinafine or flucytosine
E) Flucytosine is safe in pregnancy because it is selectively activated by fungal cytosine deaminase, which is absent in mammalian cells; because mammalian cells including fetal cells cannot convert flucytosine to its toxic 5-fluorouracil (5-FU) metabolite, no teratogenic risk exists and flucytosine can be used at any gestational age
ANSWER: C
Rationale:
All three agents covered in this module have safety concerns in pregnancy that preclude their routine use. Griseofulvin is formally contraindicated in pregnancy on the basis of teratogenicity demonstrated in animal studies (skeletal and other developmental abnormalities); it is also a CYP3A4 inducer that reduces oral contraceptive efficacy, and patients who could become pregnant must use barrier contraception during and for one month after treatment. Flucytosine is similarly contraindicated based on teratogenicity in animal models; the potential for gut-bacterial conversion to 5-fluorouracil (5-FU) — a known teratogen and antimetabolite — raises additional concern about fetal exposure even if direct mammalian cytosine deaminase activity is absent. Terbinafine has limited human pregnancy safety data; prescribing guidance recommends against use in the first trimester, and caution applies throughout pregnancy. For a patient at 14 weeks gestation with tinea capitis, deferral of systemic treatment until after delivery is preferable when clinically feasible. If systemic therapy is urgently required, specialist input should guide selection; an oral azole such as fluconazole carries its own gestational risks that vary by agent and trimester and requires careful risk-benefit assessment.
Option A: Option A is incorrect because terbinafine does not have an established favorable human safety record in pregnancy; it has limited data, is not recommended in the first trimester, and is not classified as safe for use throughout pregnancy.
Option B: Option B is incorrect because the teratogenic risks of griseofulvin and flucytosine are not confined to the first trimester of organogenesis; both drugs have broader developmental concerns and are not approved for use at any gestational age.
Option D: Option D is incorrect because natural product origin does not confer teratogenic safety; griseofulvin's derivation from Penicillium griseofulvum is pharmacologically irrelevant to its teratogenicity profile, which is established in animal studies regardless of origin.
Option E: Option E is incorrect because while mammalian cells lack cytosine deaminase and therefore do not directly convert flucytosine to 5-FU, systemic 5-FU is generated by intestinal bacterial conversion and can reach the fetal circulation; the absence of fetal cytosine deaminase does not protect the developing fetus from maternally generated 5-FU exposure.
2. A 34-year-old HIV-positive woman on a ritonavir-boosted antiretroviral regimen and a combined oral contraceptive (OC) develops tinea capitis caused by Microsporum canis. Her physician considers prescribing griseofulvin. Ritonavir is one of the most potent inhibitors of CYP3A4 (cytochrome P450 3A4) available clinically. Which statement best characterizes the pharmacological complexity of adding griseofulvin to this patient's regimen?
A) The interaction is bidirectional and potentially self-limiting: ritonavir's potent CYP3A4 inhibition will substantially blunt griseofulvin's own CYP3A4 induction effect by occupying the enzyme, reducing griseofulvin's metabolism and potentially increasing its plasma concentrations; simultaneously, the residual net CYP activity and griseofulvin's induction of CYP1A2 may still reduce OC efficacy, and an alternative antifungal with fewer CYP interactions should be strongly considered
B) Ritonavir and griseofulvin are additive CYP3A4 inhibitors; combined, they produce extreme elevation of OC hormone concentrations through shared enzyme inhibition, increasing the risk of thromboembolic complications rather than contraceptive failure
C) Griseofulvin's CYP3A4 induction will override ritonavir's CYP3A4 inhibition because induction is a transcriptional effect that operates at the gene level and cannot be blocked by competitive enzyme inhibition; the net effect is full induction of CYP3A4, substantially reducing both OC and ritonavir plasma concentrations
D) There is no clinically relevant interaction between ritonavir and griseofulvin because ritonavir's inhibition of CYP3A4 is confined to intestinal wall CYP3A4, while griseofulvin's induction affects only hepatic CYP3A4; the two effects occur in anatomically distinct compartments and do not interact
E) Griseofulvin is safe to co-administer with ritonavir because ritonavir-boosted regimens completely suppress griseofulvin's CYP3A4 induction at the transcriptional level through PXR (pregnane X receptor) antagonism, eliminating both the OC interaction and any effect on antiretroviral concentrations
ANSWER: A
Rationale:
This scenario involves a pharmacokinetic interaction of genuine complexity. Griseofulvin induces CYP3A4 through nuclear receptor-mediated transcriptional upregulation, increasing enzyme synthesis over days to weeks. Ritonavir is a potent mechanism-based CYP3A4 inhibitor that inactivates existing CYP3A4 enzyme. When both drugs are present, ritonavir substantially reduces the functional CYP3A4 pool available for metabolism of other drugs — including griseofulvin itself, which is a CYP3A4 substrate — potentially increasing griseofulvin plasma concentrations and altering its tissue exposure. Concurrently, ritonavir's CYP3A4 inhibition may blunt the induction of CYP3A4-mediated metabolism of co-substrates including OC ethinylestradiol, but griseofulvin also induces CYP1A2 (cytochrome P450 1A2), which ritonavir does not equivalently inhibit, leaving a residual pathway for OC metabolism. The net pharmacokinetic outcome is unpredictable, interactions are bidirectional, and OC failure risk cannot be fully excluded. An alternative antifungal with fewer CYP3A4 interactions — such as terbinafine, which inhibits CYP2D6 rather than inducing CYP3A4 — would be a more straightforward choice in this patient if terbinafine's coverage of M. canis were adequate.
Option B: Option B is incorrect because griseofulvin is a CYP3A4 inducer, not an inhibitor; it does not add to ritonavir's inhibitory effect, and the combined effect would not predictably elevate OC concentrations to thrombogenic levels.
Option C: Option C is incorrect because transcriptional induction and competitive/mechanism-based enzyme inhibition are not mutually exclusive processes that cancel one another in a simple hierarchy; ritonavir's inactivation of existing CYP3A4 enzyme will reduce the functional consequence of newly induced enzyme as long as ritonavir is present, and the net effect is complex rather than induction simply overriding inhibition.
Option D: Option D is incorrect because griseofulvin's CYP3A4 induction and ritonavir's CYP3A4 inhibition both occur in hepatic and intestinal CYP3A4; the separation into anatomically distinct compartments is pharmacokinetically inaccurate.
Option E: Option E is incorrect because ritonavir does not antagonize PXR (the pregnane X receptor that mediates CYP3A4 induction) — ritonavir inhibits the CYP3A4 enzyme protein itself, not the transcriptional activator, and complete suppression of griseofulvin's induction effect by ritonavir through PXR antagonism is not an established mechanism.
3. A 44-year-old man with HIV and cryptococcal meningitis is on day 9 of induction therapy with amphotericin B liposomal plus flucytosine 25 mg/kg every 6 hours. His baseline CBC was normal. Today's CBC shows WBC 1.4 × 10⁹/L, hemoglobin 88 g/L, and platelets 58 × 10⁹/L. A 2-hour post-dose flucytosine level drawn this morning is 124 mg/L. Renal function has been stable. What is the most appropriate immediate management?
A) Discontinue both amphotericin B and flucytosine immediately; the pancytopenia most likely represents amphotericin B-induced bone marrow suppression, which is the most common cause of cytopenia in this combination, and both drugs should be withheld until counts recover
B) Continue flucytosine at the current dose and schedule a bone marrow biopsy to exclude cryptococcal bone marrow infiltration as the cause of pancytopenia before attributing the cytopenia to drug toxicity
C) Reduce the flucytosine dose by 10% and recheck the CBC in 5 days; small incremental reductions preserve antifungal efficacy while gradually reducing the myelosuppressive burden
D) Switch flucytosine to intravenous administration at the same dose; intravenous delivery bypasses gut bacterial conversion of flucytosine to 5-fluorouracil (5-FU), eliminating the source of myelosuppression while maintaining systemic antifungal drug levels
E) Reduce or withhold flucytosine based on the toxic drug level — the 2-hour post-dose concentration of 124 mg/L exceeds the toxic threshold of 100 mg/L, which is the concentration above which concentration-dependent myelosuppression risk increases sharply; re-dose at a reduced dose or extended interval guided by repeat TDM (therapeutic drug monitoring), and continue amphotericin B to maintain combination antifungal activity
ANSWER: E
Rationale:
The 2-hour post-dose flucytosine concentration of 124 mg/L exceeds the established toxic threshold of 100 mg/L above which the risk of concentration-dependent myelosuppression rises sharply. Myelosuppression from flucytosine arises when gut bacterial conversion of flucytosine to 5-fluorouracil (5-FU) generates sufficient systemic 5-FU to suppress rapidly dividing bone marrow progenitor cells. The toxicity is concentration-dependent, meaning it correlates with drug exposure, and the measured level here directly explains the pancytopenia on day 9. The correct management is to reduce or temporarily hold flucytosine, then resume at a reduced dose or extended interval guided by repeat TDM targeting a 2-hour peak of 25 to 50 mg/L with troughs below 100 mg/L. Amphotericin B should be continued because its myelosuppression profile is distinct — amphotericin B's primary toxicities are nephrotoxicity and infusion reactions, not direct bone marrow suppression — and removing it from the combination would eliminate its fungicidal contribution to induction therapy. CBC monitoring twice weekly during flucytosine therapy exists specifically to detect this scenario early.
Option A: Option A is incorrect because amphotericin B does not directly cause bone marrow suppression as a primary toxicity; its principal adverse effects are nephrotoxicity and infusion-related reactions. Discontinuing both agents eliminates the combination's proven survival benefit, and the elevated flucytosine level provides a direct pharmacokinetic explanation for the cytopenia that does not require both drugs to be stopped.
Option B: Option B is incorrect because while cryptococcal bone marrow infiltration can cause cytopenia in disseminated infection, the markedly elevated flucytosine level provides a direct pharmacokinetic explanation that should be addressed immediately; performing a bone marrow biopsy before dose adjustment delays appropriate management of a pharmacologically explained toxicity.
Option C: Option C is incorrect because a 10% dose reduction is inadequate when the measured level is 124 mg/L — substantially above the 100 mg/L toxic threshold; TDM-guided dose adjustment to achieve a peak of 25 to 50 mg/L requires a more meaningful reduction than 10%, and waiting 5 days before rechecking CBC allows further marrow suppression in the interim.
Option D: Option D is incorrect because the route of flucytosine administration does not eliminate gut bacterial 5-FU generation; flucytosine administered intravenously distributes to the gastrointestinal tract and is still subject to gut bacterial deamination, so switching routes does not meaningfully reduce 5-FU exposure.
4. A 58-year-old man with moderate chronic lower back pain is managed with tramadol 100 mg twice daily, which provides adequate analgesia. He is started on terbinafine 250 mg once daily for toenail onychomycosis. Over the following two weeks, he reports that his pain control has deteriorated significantly despite continuing the same tramadol dose. Which pharmacokinetic interaction most plausibly explains the loss of analgesia?
A) Terbinafine induces CYP3A4, accelerating the hepatic N-demethylation of tramadol to its inactive N-desmethyl metabolite, thereby shunting tramadol away from the active O-demethylation pathway and reducing overall opioid receptor activity
B) Terbinafine inhibits the renal tubular transporter responsible for tramadol excretion, increasing tramadol plasma concentrations and producing paradoxical opioid-induced hyperalgesia through mu-receptor desensitization
C) Terbinafine forms a stable complex with tramadol in the gastrointestinal tract before absorption, reducing tramadol oral bioavailability by approximately 60% and producing subtherapeutic plasma tramadol concentrations
D) Terbinafine inhibits CYP2D6, the enzyme responsible for O-demethylation of tramadol to its pharmacologically active M1 metabolite (O-desmethyltramadol); reduced M1 production decreases opioid receptor activation because tramadol's parent compound has substantially lower affinity for the mu-opioid receptor than M1, effectively converting the patient to a poor CYP2D6 metabolizer phenotype
E) Terbinafine inhibits CYP2D6 and simultaneously induces CYP3A4; the combined effect increases tramadol N-demethylation to the toxic M2 metabolite, which competitively antagonizes mu-opioid receptors and reduces the analgesic response to tramadol's remaining M1 metabolite
ANSWER: D
Rationale:
Tramadol is a prodrug with a complex pharmacology that depends critically on CYP2D6-mediated O-demethylation. The parent tramadol compound has relatively weak affinity for the mu-opioid receptor, providing modest intrinsic analgesia. CYP2D6 converts tramadol to O-desmethyltramadol (M1), which has approximately 200-fold higher affinity for the mu-opioid receptor than the parent compound; the analgesic efficacy of tramadol is therefore predominantly mediated through M1. Terbinafine is a potent mechanism-based inhibitor of CYP2D6, irreversibly inactivating the enzyme. When CYP2D6 activity is substantially reduced by terbinafine, O-demethylation of tramadol to M1 is impaired, M1 concentrations fall, and opioid receptor activation — and therefore analgesia — is reduced. This functionally converts the patient to a poor CYP2D6 metabolizer for tramadol, explaining the clinical loss of pain control at an unchanged tramadol dose. This interaction is clinically significant and potentially dangerous if the clinician responds by escalating the tramadol dose without recognizing the pharmacokinetic cause.
Option A: Option A is incorrect because terbinafine does not induce CYP3A4; its primary CYP interaction is potent inhibition of CYP2D6. N-demethylation of tramadol by CYP3A4 produces N-desmethyltramadol (M2), which has minimal opioid receptor activity but its production does not explain loss of analgesia caused by CYP3A4 induction in the setting of terbinafine.
Option B: Option B is incorrect because terbinafine does not inhibit the renal tubular transporters responsible for tramadol excretion to a clinically meaningful degree; the interaction is hepatic and metabolic, not renal. Opioid-induced hyperalgesia from increased tramadol concentrations is not the explanation here, and tramadol accumulation would be expected to maintain or increase rather than decrease analgesia.
Option C: Option C is incorrect because terbinafine does not form a pharmacokinetic chelation complex with tramadol in the gastrointestinal tract that reduces tramadol absorption; this mechanism is not established and the interaction is entirely intrahepatic metabolic.
Option E: Option E is incorrect because terbinafine inhibits CYP2D6 but does not induce CYP3A4; M2 (N-desmethyltramadol) is not a mu-opioid receptor antagonist and does not competitively displace M1 from opioid receptors — this mechanism is pharmacologically fabricated.
5. A 55-year-old man is anticoagulated with warfarin (target INR (international normalized ratio) 2.0–3.0) for a recent proximal deep vein thrombosis (DVT). His INR has been stable at 2.4 for six weeks. He is prescribed griseofulvin for tinea capitis. Three weeks later he presents with new right calf swelling and ultrasound confirms a new distal DVT extension. His INR today is 1.5. Which statement best explains this clinical deterioration and identifies the correct management response?
A) Griseofulvin has displaced warfarin from plasma protein binding, paradoxically increasing warfarin's free fraction and renal clearance; the increased renal excretion of unbound warfarin has reduced total warfarin concentrations and INR; the correct management is to switch to a direct oral anticoagulant (DOAC) that is not protein-bound
B) Griseofulvin has induced CYP3A4 and CYP1A2, increasing the hepatic metabolism of warfarin's S-enantiomer and reducing warfarin plasma concentrations and anticoagulant effect; the INR has fallen below therapeutic range, explaining the new thrombus; warfarin dose should be increased with frequent INR monitoring during the remainder of the griseofulvin course and reduced again when griseofulvin is stopped
C) Griseofulvin inhibits vitamin K epoxide reductase, the same enzyme targeted by warfarin; at low doses griseofulvin produces additive anticoagulation, but at the doses used for tinea capitis it paradoxically activates a compensatory vitamin K recycling pathway that reduces anticoagulant efficacy
D) The new DVT is unrelated to griseofulvin; the INR of 1.5 reflects dietary changes or intercurrent illness rather than a drug interaction, and the correct management is to review the patient's diet for vitamin K intake changes before adjusting the warfarin dose
E) Griseofulvin inhibits CYP2C9, which metabolizes the pharmacologically active S-warfarin enantiomer; reduced S-warfarin clearance should produce warfarin accumulation and INR elevation, making the observed INR reduction inconsistent with griseofulvin as the cause; another explanation for the falling INR should be sought
ANSWER: B
Rationale:
Griseofulvin induces CYP3A4 and CYP1A2, increasing the hepatic metabolism of warfarin. Warfarin's anticoagulant activity resides predominantly in the S-enantiomer, which is metabolized by CYP2C9; however, both enantiomers contribute to overall drug exposure, and CYP3A4 induction by griseofulvin accelerates warfarin R-enantiomer clearance and increases overall warfarin elimination. The net clinical effect is reduced warfarin plasma concentrations, reduced anticoagulant activity, and a falling INR. In this patient, the INR has dropped from a therapeutic 2.4 to a subtherapeutic 1.5 over three weeks of griseofulvin — precisely the time course expected for CYP enzyme induction to develop — and this subtherapeutic anticoagulation has allowed extension of his existing venous thromboembolism. Correct management requires increasing the warfarin dose to restore the INR to the therapeutic range of 2.0 to 3.0, with INR checks every one to two weeks during the griseofulvin course, and an anticipatory warfarin dose reduction when griseofulvin is discontinued as induced enzyme activity returns to baseline over two to four weeks.
Option A: Option A is incorrect because protein binding displacement is not the mechanism of the griseofulvin-warfarin interaction; the dominant mechanism is CYP enzyme induction reducing warfarin clearance, and switching to a DOAC is not indicated simply because of a drug interaction that can be managed with dose adjustment and monitoring.
Option C: Option C is incorrect because griseofulvin does not inhibit vitamin K epoxide reductase and does not interact with warfarin's pharmacodynamic mechanism; its warfarin interaction is entirely pharmacokinetic through CYP induction.
Option D: Option D is incorrect because a documented three-week temporal relationship between starting griseofulvin and a falling INR in a patient with no other documented changes is highly consistent with a CYP3A4 induction drug interaction; attributing the INR change to dietary causes without pharmacological investigation is inappropriate given the known interaction.
Option E: Option E is incorrect because griseofulvin does not inhibit CYP2C9; it is a CYP3A4 and CYP1A2 inducer, not a CYP2C9 inhibitor, and the falling INR is entirely consistent with CYP induction-mediated warfarin clearance rather than inhibition.
6. A 31-year-old woman with advanced HIV (CD4 count 18 cells/µL) presents to a district hospital in a resource-limited setting with confirmed cryptococcal meningitis. Amphotericin B is unavailable at this facility. Fluconazole and flucytosine are both in stock. Which induction regimen is most consistent with current guideline-endorsed evidence for this clinical scenario?
A) Fluconazole 800 mg orally once daily for four weeks as monotherapy induction followed by fluconazole 400 mg for consolidation; monotherapy at high dose is the only acceptable option when amphotericin B is unavailable and combination therapy is therefore not possible
B) Voriconazole 6 mg/kg orally twice daily on day 1 followed by 4 mg/kg twice daily plus flucytosine 25 mg/kg every 6 hours; voriconazole has superior CNS penetration compared to fluconazole and achieves higher CSF (cerebrospinal fluid) fungicidal activity against Cryptococcus neoformans
C) Fluconazole 1200 mg orally once daily plus flucytosine 25 mg/kg orally every 6 hours for 2 weeks; this combination was evaluated in the ACTA (Advancing Cryptococcal Meningitis Treatment for Africa) trial and demonstrated faster CSF sterilization and reduced 10-week mortality compared to fluconazole monotherapy, and is recommended by WHO 2022 guidelines as an alternative induction regimen when amphotericin B is unavailable
D) Flucytosine 25 mg/kg every 6 hours as monotherapy for 2 weeks followed by fluconazole consolidation; flucytosine monotherapy achieves sufficient early fungicidal activity in immunocompromised patients to substitute for the combination when resource constraints prevent use of the complete regimen
E) Fluconazole 400 mg twice daily plus itraconazole 200 mg twice daily for 2 weeks; dual azole therapy provides complementary CYP51 inhibition at different binding sites on the lanosterol demethylase enzyme, producing synergistic antifungal activity equivalent to the amphotericin B plus flucytosine combination
ANSWER: C
Rationale:
When amphotericin B is unavailable, the WHO 2022 guidelines for cryptococcal disease and the evidence base from the ACTA (Advancing Cryptococcal Meningitis Treatment for Africa) trial support fluconazole 1200 mg orally once daily combined with flucytosine 25 mg/kg every 6 hours for two weeks of induction as an alternative to the preferred amphotericin B-based regimen. The ACTA trial, conducted in sub-Saharan Africa, demonstrated that oral fluconazole plus flucytosine achieved faster cerebrospinal fluid sterilization (higher early fungicidal activity) and reduced 10-week mortality compared to fluconazole monotherapy, establishing this combination as the recommended alternative when amphotericin B cannot be used. The pharmacological rationale is complementary: fluconazole impairs ergosterol synthesis through CYP51 inhibition, which may also enhance flucytosine uptake by altering membrane composition, while flucytosine adds a distinct antimetabolite mechanism targeting nucleic acid synthesis.
Option A: Option A is incorrect because fluconazole monotherapy for induction, even at higher doses (800 mg), is inferior to combination therapy and is the last resort option when both amphotericin B and flucytosine are unavailable; when flucytosine is available, it should be combined with fluconazole, not omitted.
Option B: Option B is incorrect because voriconazole plus flucytosine is not a guideline-endorsed alternative induction regimen for cryptococcal meningitis; voriconazole has some activity against Cryptococcus but has not been evaluated in the specific clinical trials informing current guidelines, and fluconazole is preferred over voriconazole for cryptococcal disease.
Option D: Option D is incorrect because flucytosine should never be used as monotherapy for cryptococcal meningitis or any serious fungal infection; primary resistance exists in some isolates, secondary resistance emerges rapidly with monotherapy, and no clinical trial supports flucytosine monotherapy for cryptococcal meningitis induction.
Option E: Option E is incorrect because dual azole therapy (fluconazole plus itraconazole) is not a guideline-endorsed induction regimen; azoles all inhibit CYP51 at overlapping or identical binding sites and combining them does not produce meaningful synergy, while the increased risk of drug interactions and additive toxicity makes this approach pharmacologically irrational.
7. An 8-year-old boy weighing 27 kg presents with tinea capitis confirmed by culture as Trichophyton tonsurans. The physician opts for oral terbinafine rather than griseofulvin given the T. tonsurans etiology. Which of the following represents the correct terbinafine dose and rationale for this child?
A) Terbinafine 250 mg once daily, the standard adult dose, because pediatric and adult pharmacokinetics for terbinafine are equivalent above age 6, and weight-based dosing provides no advantage over fixed adult dosing in school-age children
B) Terbinafine 62.5 mg once daily because all pediatric doses of terbinafine are standardized at 62.5 mg regardless of weight; above the minimum therapeutic threshold, increasing the dose provides no additional efficacy and only increases adverse effect risk
C) Terbinafine 187.5 mg once daily, calculated as 7 mg/kg/day × 27 kg, rounded to the nearest available tablet strength; weight-based milligram-per-kilogram dosing is preferred over bracket-based dosing for all drugs in pediatric patients to minimize inter-patient concentration variability
D) Terbinafine 125 mg once daily, based on weight-based dosing brackets: below 20 kg use 62.5 mg, 20 to 40 kg use 125 mg, above 40 kg use 250 mg; at 27 kg this child falls in the 20 to 40 kg bracket, making 125 mg once daily the correct dose for the duration of tinea capitis treatment
E) Terbinafine 250 mg every other day, alternating with a rest day; this pulsed dosing regimen achieves equivalent keratin tissue concentrations as continuous daily dosing due to terbinafine's prolonged tissue half-life, while reducing systemic drug exposure and hepatotoxicity risk
ANSWER: D
Rationale:
Terbinafine dosing in children for tinea capitis is based on published weight brackets rather than precise milligram-per-kilogram calculation, reflecting the available tablet strengths and established pediatric clinical trial data. The standard pediatric weight-based brackets are: below 20 kg, use 62.5 mg once daily; 20 to 40 kg, use 125 mg once daily; above 40 kg, use 250 mg once daily (the standard adult dose). This child weighs 27 kg, placing him squarely in the 20 to 40 kg bracket, so the correct dose is 125 mg once daily. Treatment duration for tinea capitis with terbinafine is typically four weeks for Trichophyton species. The weight-bracket approach is appropriate because terbinafine exhibits predictable pharmacokinetics in the pediatric age range and these brackets have been validated in clinical trials demonstrating efficacy and safety at these doses.
Option A: Option A is incorrect because terbinafine dosing in children is not equivalent to the adult 250 mg daily dose regardless of age; weight-based bracket dosing is the established standard for pediatric tinea capitis to avoid dose-dependent adverse effects in smaller patients.
Option B: Option B is incorrect because 62.5 mg is the dose for children below 20 kg, not a universal pediatric dose; for a 27 kg child in the 20 to 40 kg bracket, 62.5 mg would be underdosing that may produce subtherapeutic nail and scalp keratin concentrations.
Option C: Option C is incorrect because terbinafine pediatric dosing is bracket-based, not calculated as a fixed mg/kg weight-based dose; there is no established 7 mg/kg/day dosing calculation for terbinafine, and the bracket system is what appears in prescribing guidelines and clinical trial data.
Option E: Option E is incorrect because alternate-day pulsed terbinafine dosing has not been established as clinically equivalent to daily dosing for tinea capitis in children; the pulsed regimen approach has been studied for onychomycosis in adults and is not the standard recommended pediatric tinea capitis regimen.
8. A 63-year-old woman is in week 10 of terbinafine 250 mg daily for toenail onychomycosis. She has no symptoms — no jaundice, no abdominal pain, no fatigue. Routine liver function tests (LFTs) ordered by her primary care physician return with ALT (alanine aminotransferase) at 6 times the upper limit of normal (ULN); AST (aspartate aminotransferase) is 4 times ULN; bilirubin is normal. She calls her physician to ask whether she can complete the remaining two weeks of her course. What is the correct recommendation?
A) Terbinafine should be discontinued immediately; current prescribing guidance specifies that terbinafine should be stopped if ALT or AST rises above 5 times ULN even in the absence of symptoms, and this patient's ALT of 6 times ULN meets this threshold regardless of her being asymptomatic
B) Terbinafine can be continued at full dose because the patient is asymptomatic; the stopping threshold of 3 times ULN applies only to patients with concurrent symptoms such as jaundice or right upper quadrant pain, and asymptomatic LFT elevations of any magnitude do not require dose modification or discontinuation
C) Terbinafine should be dose-reduced to 125 mg once daily and LFTs repeated in one week; the idiosyncratic mechanism of terbinafine hepatotoxicity means that dose reduction reduces the immunological trigger and allows the liver injury to resolve while completing the remaining two weeks of treatment
D) Because the patient has only two weeks remaining, terbinafine should be continued to completion; the risk of stopping two weeks early is treatment failure and nail relapse, which is clinically more significant than a transient asymptomatic ALT elevation at 6 times ULN in an otherwise well patient
E) LFTs should be repeated in 72 hours before any action is taken; a single ALT value of 6 times ULN may represent a laboratory error or transient hepatic stress from a non-drug cause, and discontinuation should not occur until two consecutive elevated values are documented
ANSWER: A
Rationale:
Current prescribing guidance for terbinafine specifies two stopping thresholds based on the presence or absence of symptoms. For patients with symptoms of hepatotoxicity (jaundice, dark urine, right upper quadrant pain, fatigue), the threshold for discontinuation is ALT or AST above 3 times ULN. For asymptomatic patients, the threshold is ALT or AST above 5 times ULN. This patient has no symptoms but an ALT of 6 times ULN, which exceeds the 5-times-ULN asymptomatic stopping threshold — terbinafine should therefore be discontinued immediately. The reason the asymptomatic threshold is set at 5 times ULN (rather than requiring symptoms) is that terbinafine hepatotoxicity is idiosyncratic and can progress rapidly to severe liver injury or hepatic failure; waiting for symptoms before stopping in patients with significant asymptomatic enzyme elevation is not appropriate. Patients should be advised to report jaundice, dark urine, or abdominal pain and return promptly if symptoms develop after discontinuation.
Option B: Option B is incorrect because the stopping threshold for asymptomatic patients is 5 times ULN, not an unlimited elevation; stating that asymptomatic LFT elevations of any magnitude do not require action misrepresents prescribing guidance and could lead to serious harm if hepatotoxicity progresses unchecked.
Option C: Option C is incorrect because terbinafine hepatotoxicity is idiosyncratic and immune-mediated, not dose-dependent; dose reduction does not mitigate the underlying immunological process and continued drug exposure at any dose is inappropriate when the stopping threshold has been reached.
Option D: Option D is incorrect because the clinical priority here is patient safety, not completing the last two weeks of a cosmetic indication; at an ALT of 6 times ULN the stopping threshold has been crossed, and the risk of progressive hepatic injury from two more weeks of terbinafine substantially outweighs the benefit of onychomycosis treatment completion.
Option E: Option E is incorrect because waiting for a repeated value before acting at an ALT of 6 times ULN — well above the 5-times-ULN stopping threshold — introduces unnecessary delay; the prescribing guidance threshold does not require confirmatory repeated values before discontinuation, and prompt action is appropriate.
9. A patient with cryptococcal meningitis has been on amphotericin B liposomal plus flucytosine 25 mg/kg every 6 hours for 8 days. Twice-weekly CBC monitoring shows a WBC of 2.1 × 10⁹/L today, down from 5.8 × 10⁹/L at baseline. A flucytosine trough drawn just before the morning dose is 112 mg/L. Renal function has worsened slightly: creatinine has risen from 0.8 to 1.6 mg/dL over the past four days. What is the most appropriate management of flucytosine at this point?
A) Continue flucytosine at the current dose and increase the frequency of CBC monitoring to daily; the leukopenia is mild and monitoring without dose change is sufficient as long as the WBC does not fall below 1.0 × 10⁹/L
B) Discontinue flucytosine permanently and complete induction with amphotericin B monotherapy; once myelosuppression from flucytosine has occurred, the drug cannot be safely restarted at any dose because prior exposure sensitizes the bone marrow to lower concentrations of 5-fluorouracil (5-FU)
C) Hold flucytosine for 24 hours and administer granulocyte colony-stimulating factor (G-CSF) to stimulate bone marrow recovery; restart flucytosine at the full original dose once WBC exceeds 3.0 × 10⁹/L without adjusting the dose based on drug levels
D) Reduce the flucytosine dose by exactly 50% based on the doubling of serum creatinine; the standard pharmacokinetic rule for renally cleared drugs is to halve the dose when creatinine doubles, and this should be applied uniformly without measuring drug levels
E) Hold or reduce the flucytosine dose based on the supratherapeutic trough of 112 mg/L — which exceeds the 100 mg/L toxic threshold — and the concurrent worsening renal function reducing flucytosine clearance; determine the adjusted dose or interval by repeat TDM targeting peak 25 to 50 mg/L and trough below 100 mg/L, and continue amphotericin B throughout
ANSWER: E
Rationale:
Two concurrent pharmacokinetic problems explain the toxic flucytosine level and the resulting myelosuppression. First, the trough of 112 mg/L directly exceeds the established toxic threshold of 100 mg/L, above which concentration-dependent myelosuppression risk increases sharply; the falling WBC is the expected clinical consequence. Second, serum creatinine has risen from 0.8 to 1.6 mg/dL over four days — consistent with amphotericin B-related nephrotoxicity — and since flucytosine is eliminated almost entirely by renal excretion of unchanged drug, this reduction in GFR has reduced flucytosine clearance and raised concentrations above the safe range. The correct management is to hold or reduce flucytosine to bring concentrations back within the therapeutic window, then resume at an adjusted dose or interval guided by repeat TDM measurements targeting a 2-hour post-dose peak of 25 to 50 mg/L and a trough below 100 mg/L. Amphotericin B should be continued uninterrupted to maintain combination antifungal activity; its contribution to the induction regimen is independent of flucytosine's dose.
Option A: Option A is incorrect because continuing at the current dose when the trough is already 112 mg/L — above the toxic threshold — will maintain or worsen myelosuppression; the measured drug level provides direct evidence that dose modification is needed rather than just closer monitoring.
Option B: Option B is incorrect because flucytosine can be safely restarted at a reduced dose guided by TDM after a brief hold; there is no pharmacological basis for the claim that prior myelosuppression permanently sensitizes the marrow to 5-FU at lower concentrations — the toxicity is concentration-dependent and resolves when levels are brought back within range.
Option C: Option C is incorrect because G-CSF does not address the pharmacokinetic cause of the myelosuppression; restarting at the full original dose without dose adjustment would immediately reproduce the toxic flucytosine concentrations that caused the problem.
Option D: Option D is incorrect because a mechanical 50% dose reduction based on creatinine doubling, without measuring drug levels, does not confirm whether the adjusted dose achieves the therapeutic target; TDM-guided adjustment is explicitly preferred over creatinine-table-based fixed reductions when renal function is changing rapidly.
10. A 27-year-old woman with a history of two prior unexplained episodes of severe abdominal pain, each lasting two to three days before resolving spontaneously, presents with Microsporum canis tinea capitis. Both prior abdominal pain episodes were investigated with abdominal CT and endoscopy with normal findings. The physician plans to prescribe griseofulvin. Which action is most appropriate before initiating treatment?
A) Proceed with griseofulvin as planned; episodic self-resolving abdominal pain with normal investigation is a common presentation of irritable bowel syndrome (IBS) and does not represent a contraindication to griseofulvin
B) Screen for porphyria before prescribing griseofulvin; this patient's history of episodic severe unexplained abdominal pain with normal structural investigations is a classic presentation of acute intermittent porphyria or another acute hepatic porphyria — griseofulvin induces hepatic delta-aminolevulinic acid synthase (ALA-S1) and is absolutely contraindicated in porphyria, and initiating it in a patient with undiagnosed latent porphyria could precipitate a life-threatening acute porphyric crisis
C) Prescribe griseofulvin but co-administer a high-carbohydrate diet throughout the treatment course; carbohydrate loading suppresses ALA-S1 induction by griseofulvin through a glucose-sensing mechanism that counteracts the drug's porphyrinogenic effect
D) Prescribe griseofulvin but advise the patient to take 500 mg of vitamin B6 (pyridoxine) daily throughout the course; pyridoxine is a cofactor for ALA-S1 and competitively inhibits the excess ALA-S1 activity induced by griseofulvin, preventing porphyrin precursor accumulation
E) Prescribe griseofulvin at half the standard dose (125 mg/kg/day microsize instead of 250 mg/kg/day); the porphyrinogenic effect of griseofulvin is dose-dependent, and half-dose therapy produces insufficient ALA-S1 induction to trigger an acute attack even in patients with latent porphyria
ANSWER: B
Rationale:
This patient's history warrants porphyria screening before prescribing griseofulvin. The clinical presentation — recurrent episodes of severe abdominal pain lasting days, normal structural investigations of the gastrointestinal tract — is a hallmark presentation of acute hepatic porphyrias, particularly acute intermittent porphyria (AIP). These episodes represent incomplete or spontaneously resolving acute attacks in a patient with latent porphyria who has not yet been diagnosed. Griseofulvin is absolutely contraindicated in all forms of porphyria because it induces hepatic delta-aminolevulinic acid synthase (ALA-S1), the rate-limiting enzyme of heme biosynthesis. In a patient with a partial downstream enzymatic defect (latent porphyria), this ALA-S1 induction overwhelms the pathway's capacity, causing toxic accumulation of porphyrin precursors (ALA and porphobilinogen) and precipitating a full acute attack with severe abdominal pain, neuropsychiatric symptoms, autonomic instability, and potentially motor neuropathy. Appropriate screening includes urine porphobilinogen and ALA measurement during a symptomatic episode, or during an asymptomatic period if the clinical suspicion is high, with specialist referral.
Option A: Option A is incorrect because the described history — severe episodic abdominal pain lasting days with completely normal structural investigations — is not a typical IBS presentation; IBS characteristically produces chronic lower abdominal discomfort rather than discrete severe episodic attacks, and this clinical pattern should prompt porphyria exclusion before any porphyrinogenic drug is prescribed.
Option C: Option C is incorrect because high-carbohydrate loading is used as a therapeutic measure during an acute porphyric attack to suppress ALA-S1 activity, but it does not reliably prevent ALA-S1 induction by an ongoing porphyrinogenic drug stimulus; continuing griseofulvin while supplementing carbohydrates does not adequately protect a patient with latent porphyria.
Option D: Option D is incorrect because pyridoxine does not competitively inhibit ALA-S1 to prevent griseofulvin-induced porphyrin precursor accumulation; pyridoxine is a cofactor for ALA-S1, meaning it supports rather than inhibits the enzyme, and supplementation would not protect against griseofulvin's porphyrinogenic effect.
Option E: Option E is incorrect because griseofulvin's porphyrinogenic effect operates through ALA-S1 induction, which is a transcriptional mechanism that does not have a simple dose-response threshold guaranteeing safety at half-dose; in a patient with true latent porphyria, any degree of ALA-S1 induction above the baseline capacity of the defective downstream enzyme can precipitate an attack.
11. A 22-year-old man is in week 6 of a 12-week terbinafine course for toenail onychomycosis. His psychiatrist independently initiates atomoxetine for newly diagnosed attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is a selective norepinephrine reuptake inhibitor with a narrow therapeutic index that is metabolized almost exclusively by CYP2D6 to its primary active metabolite; CYP2D6 poor metabolizers experience substantially higher atomoxetine exposure, more frequent adverse effects (tachycardia, hypertension, appetite suppression, urinary retention), and require dose reduction. Which statement best describes the pharmacological risk and appropriate prescribing action in this patient?
A) No interaction is expected because terbinafine is an antifungal and atomoxetine is a psychiatric drug; pharmacokinetic interactions between drugs prescribed for different therapeutic indications by different specialists occur only when the drugs share the same organ system target, not when they share only a metabolic enzyme
B) The interaction is clinically negligible because atomoxetine's volume of distribution is very large (approximately 0.85 L/kg), distributing it widely into tissues; the resulting low plasma concentrations mean that even a 50% reduction in CYP2D6-mediated clearance would produce only a minor increase in plasma atomoxetine levels
C) Terbinafine inhibits CYP3A4, which is atomoxetine's primary metabolic pathway; the interaction produces accelerated atomoxetine clearance and subtherapeutic concentrations, requiring dose escalation rather than reduction
D) Terbinafine's potent mechanism-based CYP2D6 inhibition will substantially reduce atomoxetine clearance, converting this patient pharmacokinetically to a CYP2D6 poor metabolizer with significantly elevated atomoxetine exposure; given atomoxetine's narrow therapeutic index, the psychiatrist should either start atomoxetine at a reduced initial dose with slow titration and cardiovascular monitoring, or defer initiation until terbinafine is completed and CYP2D6 activity has recovered
E) The interaction is self-correcting because atomoxetine itself is a CYP2D6 inhibitor; co-administration of two CYP2D6 inhibitors saturates the enzyme's binding capacity bilaterally, resulting in mutual competitive inhibition that paradoxically preserves atomoxetine's clearance at near-normal rates
ANSWER: D
Rationale:
Atomoxetine is metabolized almost exclusively by CYP2D6 to its primary metabolite 4-hydroxyatomoxetine; this pathway governs atomoxetine's systemic exposure, duration of action, and adverse effect profile. In CYP2D6 poor metabolizers (approximately 7% of Caucasian populations), atomoxetine AUC (area under the concentration-time curve) is approximately 10-fold higher than in extensive metabolizers, and the incidence of cardiovascular adverse effects (tachycardia, hypertension) and other toxicities (urinary retention, hepatotoxicity) is substantially greater. Atomoxetine prescribing information explicitly requires dose reduction in patients who are CYP2D6 poor metabolizers or who are receiving strong CYP2D6 inhibitors. Terbinafine is one of the most potent mechanism-based CYP2D6 inhibitors available clinically; its irreversible enzyme inactivation converts even an extensive metabolizer to a functional poor metabolizer phenotype for CYP2D6 substrates, including atomoxetine. Starting atomoxetine at the standard initiation dose in a patient actively taking terbinafine risks marked atomoxetine accumulation with cardiovascular and other toxicities. The two-specialist scenario in this question is a realistic clinical risk, highlighting the importance of comprehensive medication review across prescribers. The correct approach is either to start atomoxetine at the reduced dose specified for CYP2D6 poor metabolizers with careful titration and cardiovascular monitoring, or to defer atomoxetine until terbinafine is completed and CYP2D6 enzyme activity has recovered (which may take several weeks given mechanism-based irreversible inhibition).
Option A: Option A is incorrect because pharmacokinetic interactions through shared metabolic enzymes occur regardless of the therapeutic indications of the co-administered drugs; CYP2D6 inhibition by terbinafine is a pharmacokinetic property of the drug, not limited to drugs sharing a disease-system target.
Option B: Option B is incorrect because volume of distribution governs tissue distribution and affects the concentration profile over time, but does not protect against reduced clearance; a large volume of distribution combined with reduced CYP2D6 clearance produces a longer half-life and sustained elevated plasma concentrations rather than mitigating accumulation.
Option C: Option C is incorrect because terbinafine's primary and clinically important CYP interaction is inhibition of CYP2D6, not CYP3A4; atomoxetine is a CYP2D6 substrate, not a CYP3A4 substrate to a clinically relevant degree, and the interaction produces reduced clearance rather than accelerated clearance.
Option E: Option E is incorrect because while atomoxetine does have some CYP2D6 inhibitory activity itself, this does not produce mutual competitive inhibition that preserves normal clearance; in a patient with terbinafine-inactivated CYP2D6, there is effectively no functional enzyme to be competitively inhibited by atomoxetine, and the claim of a self-correcting mutual inhibition is pharmacologically incoherent.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.